By NewsDesk  @infectiousdiseasenews Morristown, NJ pharmaceutical company, Melinta Therapeutics announced this week that their lipoglycopeptide antibiotic, KIMYRSA™ (oritavancin), is now commercially...

Melinta Therapeutics, LLC (Melinta), today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin)  for the treatment of adult patients with acute bacterial skin...

By NewsDesk  @infectiousdiseasenews In late December 2019, antibiotic development and commercialization company, Melinta Therapeutics, Inc. initiated a voluntary Chapter 11 process to effectuate restructuring...

Melinta Therapeutics, Inc. , a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of intravenous and oral formulations...